{"preliminary_commentary":{"by_channel":{"x_thread":3},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":false},"commentary_summary":null,"name":"NCT04526899","nct_id":"NCT04526899","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=nct04526899. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":null,"arms":[{"description":null,"label":"BNT111 + cemiplimab","type":"EXPERIMENTAL"},{"description":null,"label":"BNT111 monotherapy","type":"EXPERIMENTAL"},{"description":null,"label":"Cemiplimab monotherapy","type":"EXPERIMENTAL"}],"collaborators":["Regeneron Pharmaceuticals"],"completion_date":{"date":"2025-11-24","type":"ACTUAL"},"conditions":["Melanoma Stage III","Melanoma Stage IV","Unresectable Melanoma"],"enrollment":{"count":184,"type":"ACTUAL"},"has_results":true,"interventions":[{"name":"BNT111","otherNames":[],"type":"BIOLOGICAL"},{"name":"Cemiplimab","otherNames":[],"type":"BIOLOGICAL"}],"last_update":"2026-01-08","lead_sponsor":"BioNTech SE","official_title":"Open-label, Randomized Phase II Trial With BNT111 and Cemiplimab in Combination or as Single Agents in Patients With Anti-PD-1-refractory/Relapsed, Unresectable Stage III or IV Melanoma","overall_status":"COMPLETED","phases":["PHASE2"],"primary_completion_date":{"date":"2024-01-25","type":"ACTUAL"},"primary_outcomes":[{"measure":"Arm 1: Objective Response Rate (ORR)","timeFrame":"Up to 24 months"}],"references":[],"start_date":{"date":"2021-05-19","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"A Study to Investigate the Novel Agent BNT111 and Cemiplimab in Combination or as Single Agents in Patients With Advanced Melanoma That Has Not Responded to Other Forms of Treatment","url":"https://clinicaltrials.gov/study/NCT04526899"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/nct04526899"}